Most Immunosuppressive Drugs Not Linked to Risk for Cancer
MONDAY, Aug. 28, 2023 (HealthDay News) — For patients with ocular inflammatory disease (OID), short-term therapy with commonly used immunosuppressive drug classes and many drugs is not associated with an increased risk for cancer incidence, according…
Learn MoreWegovy podría ser una nueva opción valiosa para los pacientes con insuficiencia cardiaca
VIERNES, 25 de agosto de 2023 (HealthDay News) — Wegovy (semaglutida), un medicamento para perder peso, y un medicamento relacionado dirigido a la diabetes, Ozempic, ya han alterado el tratamiento tanto de la obesidad como de la diabetes, y las venta…
Learn MoreOxyContin: What It Is, Side Effects, Precautions & Abuse
You may have heard of the painkiller OxyContin and wonder about its pros and cons.To help you better weigh its benefits and risks for pain management, this overview will discuss what OxyContin is, how it’s used, how it’s abused, and its side effects, …
Learn MoreWegovy May Be Valuable New Option for Heart Failure Patients
FRIDAY, Aug. 25, 2023 (HealthDay News) — Weight-loss drug Wegovy (semaglutide) and its diabetes-focused cousin, Ozempic, have already upended the treatment of both obesity and diabetes, with sales of both drugs skyrocketing.Now, injected Wegovy could…
Learn MoreUSPSTF Reaffirms Recommendation of PrEP for Those at Increased HIV Risk
TUESDAY, Aug. 22, 2023 (HealthDay News) — The U.S. Preventive Services Task Force (USPSTF) recommends prescription of preexposure prophylaxis (PrEP) with effective antiretroviral therapy for individuals at increased risk for HIV acquisition. This rec…
Learn MoreTardive Dyskinesia Has Considerable Impact on Multiple Domains
TUESDAY, Aug. 22, 2023 (HealthDay News) — Tardive dyskinesia (TD) has a considerable impact on physical, psychological, social, and professional lives, according to a study published in the May/June issue of the Journal of Clinical Psychiatry.Rakesh …
Learn MoreBudesonide Yields Durable Reduction in eGFR for IgA Nephropathy
MONDAY, Aug. 21, 2023 (HealthDay News) — For patients with immunoglobulin A (IgA) nephropathy, nine months of treatment with targeted-release formulation of budesonide (Nefecon) yields a greater reduction in estimated glomerular filtration rate (eGFR…
Learn MoreAppeals Court Upholds Restrictions on Mifepristone
THURSDAY, Aug. 17, 2023 (HealthDay News) — The abortion pill mifepristone should remain legal in the United States, but with significant restrictions on access to it, a federal appeals court ruled Wednesday. The decision, issued by the U.S. Court of …
Learn MoreOral Piroxicam Plus Levonorgestrel Increases Efficacy of Emergency Contraception
THURSDAY, Aug. 17, 2023 (HealthDay News) — Oral piroxicam coadministered with levonorgestrel improves the efficacy of emergency contraception (EC), according to a study published online Aug. 16 in The Lancet.Raymond Hang Wun Li, M.D., from the Univer…
Learn MoreMost Alzheimer’s Patients May Be Ineligible for Newly Approved Drugs
THURSDAY, Aug. 17, 2023 (HealthDay News) — Two recently approved treatments offer newfound hope for patients in the early stages of Alzheimer’s disease, but most people who could benefit will likely be deemed ineligible, a new study finds.Alzheimer’…
Learn More